BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is being compared against standard chemotherapy drugs, doxorubicin or paclitaxel, ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

The payoff in lives and hospital time saved runs at about 100 to 1 per dollar invested, which is a great deal by any standard ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

The immune system’s role is usually seen as wiping out invading pathogens like bacteria and viruses, but several types of ...

Since COVID, there've been growing initiatives in Africa to start producing vaccines and medicines locally, thus gaining greater independence from global supply chains. But are these schemes ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

The NHS has announced that it will fast-track patients with advanced head and neck cancers in England into a clinical trial ...